Physician profile
Robert P Mee
NPI 1386675064
$1,075.02
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $884 · 2020: $156 · 2021: $15.48 · 2022: $19.17.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $180.06 | 2019-2020 | |
| Amgen INC. | $153.21 | 2019-2022 | |
| Pfizer INC. | $134.96 | 2019-2020 | |
| Glaxosmithkline, LLC. | $119.13 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.07 | 2019-2020 | |
| Novo Nordisk INC | $77.40 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $61.13 | 2019 | |
| Janssen Pharmaceuticals, INC | $60.06 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $42.73 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.41 | 2019 | |
| Ironshore Pharmaceuticals INC. | $29.89 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $28.93 | 2019 | |
| Amarin Pharma, INC. | $14.60 | 2020 | |
| Lilly USA, LLC | $12.77 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $12.43 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $11.24 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.